Latest Commercialisation News

Page 3 of 239
Anson Resources says its proprietary pre-treatment process removed iron to undetectable levels from a third-party lithium brine in a single pass, while retaining lithium within its stated tolerance. The company is now discussing potential technology sales, although no transaction or financial benefit has been secured.
Maxwell Dee
Maxwell Dee
10 Nov 2026
Calix has signed a SAFE with an unnamed strategic investor for a potential A$10 million contribution to its Zesty green iron demonstration project in Western Australia. The funding strengthens the project’s matched-financing position, but construction still depends on full finance, approvals and a positive Final Investment Decision.
Victor Sage
Victor Sage
10 Nov 2026
EVE Health has signed a binding agreement giving it a 75% share of distributable profit from compounded men’s sexual health products in Australia. The capital-light arrangement preserves EVE’s intellectual property ownership, but provides no minimum volumes or guaranteed revenue.
Victor Sage
Victor Sage
10 Nov 2026
Pacific Lime and Cement has secured firm commitments for a A$50 million placement while advancing a proposed US$15 million convertible note with the United States International Development Finance Corporation. The funding is aimed at moving its Papua New Guinea lime, cement, port and industrial precinct projects towards construction and commercialisation.
Victor Sage
Victor Sage
9 Nov 2026
Biotron CEO and executive director Glenn Gilbert has started more than two months ahead of schedule, immediately taking charge of a strategic review centred on SedRx. The review will also test development priorities, capital allocation and partnering options across the company’s drug portfolio.
Ada Torres
Ada Torres
9 Nov 2026
Memphasys has secured its first New Zealand commercial agreement for Felix, committing a government-operated Auckland IVF clinic to a minimum of 1,200 cartridges over two years. The deal expands the device’s installed-clinic footprint, although undisclosed pricing leaves its financial contribution unclear.
Ada Torres
Ada Torres
9 Nov 2026
Starpharma is targeting a December start for first-in-human testing of its lead DEP HER2-Lu radiopharmaceutical, subject to ethics approval, as it shifts decisively toward targeted oncology. The company also outlined stronger funding, majority ownership of Petalion’s FAP program and a proposed Chair transition at its 2026 AGM.
Ada Torres
Ada Torres
6 Nov 2026
Clinuvel has outlined a multi-year expansion from peptide therapeutics into polymers, long-acting injectables, devices and digital health, backed by A$220 million of planned FY2027-FY2030 spending. The strategy comes with a near-term setback: first patient treatment in the CUV107 vitiligo study has been delayed to February 2027.
Victor Sage
Victor Sage
6 Nov 2026
US Medicare has set a national outpatient payment of US$31,265 for Epiminder’s Minder System implant procedure from 1 January 2027, up 13% on the 2026 rate. The decision gives hospitals a defined reimbursement benchmark ahead of Epiminder’s planned US commercial launch.
Ada Torres
Ada Torres
6 Nov 2026
Anagenics has sold its haircare technology and évolis intellectual property to York St Brands for A$2.5 million upfront, while retaining exposure to future product sales through an eight-year earn-out. The deal follows the company’s first full-year profit and gives it more cash to simplify its portfolio.
Victor Sage
Victor Sage
5 Nov 2026
Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.
Victor Sage
Victor Sage
4 Nov 2026
Marine Biomedical has secured US FDA 510(k) clearance for PearlBone, giving Orthocell a clearer path into bone regeneration through its 12% strategic stake and distribution rights. The commercial opportunity is advancing, but revenue, launch timing and definitive distribution arrangements remain undisclosed.
Ada Torres
Ada Torres
3 Nov 2026

Browse the archive

Full archive